Saeki, Hidehisa

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 638

Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Kaino, H., & Nagata, T. (2020) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 242

Japanese guidelines for atopic dermatitis 2017

Katayama, I., Aihara, M., Ohya, Y., Saeki, H., Shimojo, N., Shoji, S., Taniguchi, M., & Yamada, H. (2017) · Allergology International

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 149

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis

Nakagawa, H., Nemoto, O., Igarashi, A., Saeki, H., Murata, R., Kaino, H., & Nagata, T. (2020) · The Journal of Dermatology

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 105

Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial

Beck, L. A., Bieber, T., Weidinger, S., Tauber, M., Saeki, H., Irvine, A. D., Eichenfield, L. F., Werfel, T., Arlert, P., Jiang, L., et al. (2023) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 56

Phase 2, randomized, double‐blind, placebo‐controlled, 4‐week study to evaluate the safety and efficacy of OPA‐ 15406 (difamilast), a new topical selective phosphodiesterase type‐4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis

Saeki, H., Baba, N., Oshiden, K., Abe, Y., & Tsubouchi, H. (2020) · The Journal of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 43

Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*

Thomas, K. S., Apfelbacher, C. A., Chalmers, J. R., Simpson, E., Spuls, P. I., Gerbens, L. A. A., Williams, H. C., Schmitt, J., Gabes, M., Howells, L., et al. (2021) · British Journal of Dermatology

Dermatology and Skin DiseasesDelphi Technique in Research

Cited by 13